Pfizer’s lung cancer drug fails to meet trial objectives
Dacomitinib, Pfizer's candidate for the treatment of advanced non-small cell lung cancer, has produced disappointing results in late-stage clinical trials, the company has said.
In a comparative trial versus erlotinib, the Pfizer drug failed to show a statistically significant improvement in progression-free survival. Dacomitinib also failed to prolong cancer survival in a placebo-controlled trial.
In other media coverage about Pfizer today, Forbes has analysed its expectations for the pharma giant's fourth-quarter earnings for 2013, due to be announced tomorrow, 28th January.
Trefis Team, contributor, Forbes.
Related news:
Pfizer lung cancer treatment misses goals in two studies (The Wall Street Journal).
Pfizer says lung cancer drug fails two late-stage studies (Reuters).
Pfizer earnings preview: cost-cutting to offset patent losses (Forbes).